경남세푸록심나트륨주750mg 효능·효과
경남세푸록심나트륨주750mg 복용법 (용법·용량)
경남세푸록심나트륨주750mg 부작용·주의사항
전체 12개 항목 펼치기/접기
1. 다음 환자에는 투여하지 말 것
2. 다음 경우에는 신중히 투여할 것
3. 이상반응
4. 일반적 주의
5. 상호작용
6. 임부 및 수유부에 대한 투여
7. 소아에 대한 투여
8. 고령자에 대한 투여
9. 임상검사치에의 영향
10. 과량투여시의 처치
11. 적용상의 주의
12. 기타
경남세푸록심나트륨주750mg 성분·함량
1바이알 중 기준
| 성분 | 영문 | 분량 |
|---|---|---|
| 세푸록심나트륨 | Cefuroxime Sodium | 750 밀리그램 |
🌐 해외(미국) 정보 — 세푸록심나트륨
미국 FDA·NLM 자료 · 2026-09-30 기준이 성분은 한국어 번역이 없습니다(검수 전 자동 번역 게시는 멈춰 두었습니다). 아래는 미국 FDA 원문입니다 — 원문 라벨(DailyMed).
미국에서 쓰이는 곳(적응증)
영어 원문 (미국 FDA 라벨)
Cefuroxime axetil tablets are a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria: ( 1 ) Pharyngitis/tonsillitis (adults and pediatric patients) ( 1.1 ) Acute bacterial otitis media (pediatric patients) ( 1.2 ) Acute bacterial maxillary sinusitis (adults and pediatric patients) ( 1.3 ) Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older) ( 1.4 ) Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older) ( 1.5 ) Uncomplicated urinary tract infections (adults and pediatric patients 13 years and older) ( 1.6 ) Uncomplicated gonorrhea (adults and pediatric patients 13 years and older) ( 1.7 ) Early Lyme disease (adults and pediatric patients 13 years and older) ( 1.8 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Pharyngitis/Tonsillitis Cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenes . Limitations of Use The efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical …
쓰면 안 되는 경우
영어 원문 (미국 FDA 라벨)
Cefuroxime axetil tablets are contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil tablets or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). Known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil tablets or to other β-lactams (e.g., penicillins and cephalosporins). ( 4 )
주요 경고·주의
영어 원문 (미국 FDA 라벨)
Serious hypersensitivity (anaphylactic) reactions: In the event of a serious reaction, discontinue cefuroxime axetil and institute appropriate therapy. ( 5.1 ) Clostridioides difficile- associated diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. ( 5.2 ) 5.1 Anaphylactic Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on β-lactam antibacterials, including cefuroxime axetil [see Adverse Reactions (6.2) ] . These reactions are more likely to occur in individuals with a history of β-lactam hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Cefuroxime axetil is contraindicated in patients with a known hypersensitivity to cefuroxime axetil or other β-lactam antibacterial drugs [see Contraindications (4) ] . Before initiating therapy with cefuroxime axetil, inquire about previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, discontinue cefuroxime axetil and institute appropriate therapy. 5.2 Clostridioides difficile -Associated Diarrhea Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefuroxime axetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with …
임신·특수 환자
영어 원문 (미국 FDA 라벨)
8.1 Pregnancy Risk Summary Available data from published epidemiologic studies, case series, and case reports over several decades with cephalosporin use, including cefuroxime axetil, in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . In studies in pregnant mice and rats administered oral cefuroxime axetil during organogenesis at 14 and 9 times the maximum recommended human dose (MRHD) based on body surface area, respectively, there were no adverse developmental outcomes (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. …
미국 부작용 보고(FAERS)에 많이 나온 증상
미국 FDA에 접수된 이 성분 관련 보고 15,670건 가운데 많이 적힌 증상입니다. 보고 수는 약 때문이라는 증거가 아니며, 많이 쓰는 약일수록 많아집니다. 증상 이름의 한국어는 AI 번역(참고용)이라 영어 원어를 함께 적었습니다.
- 1 호흡 곤란dyspnoea1,030
- 2 약효 없음drug ineffective969
- 3 설사diarrhoea943
- 4 적응증 외 사용off label use904
- 5 폐렴pneumonia844
- 6 발열pyrexia794
- 7 피로fatigue782
- 8 두통headache707
- 9 불안anxiety705
- 10 급성 신장 손상acute kidney injury689
- 11 구토vomiting687
- 12 만성 신장병chronic kidney disease678
미국 리콜 기록
FDA 리콜 기록이 없습니다.
출처: 미국 FDA openFDA(라벨·FAERS·리콜), 미국 국립의학도서관 RxNorm · DailyMed 원문 라벨. 한국어는 오픈드럭 서버 AI(gemma)가 자동 번역한 참고용(사람 검수 전)으로 오역이 있을 수 있으니 반드시 원문을 확인하세요.
허가 정보
- 품목기준코드
- 200902345
- 허가 구분
- 신고 · 완제의약품
- 상태
- 취하 (2025.06.23)
- 위탁 제조
- 한국유니온제약(주)
- 저장 방법
- 밀봉용기, 25℃이하 보관
- 사용 기간
- 제조일로부터 36 개월
- 포장 단위
- 자사포장단위
- ATC 코드
- J01DC02
- 표준코드
- 8806476021608
- 최근 변경
- 2024.07.18
허가 변경 이력
- · 사용상주의사항변경(부작용포함), 2024-07-18
- · 사용상주의사항변경(부작용포함), 2023-09-08
- · 사용상주의사항변경(부작용포함), 2019-01-24
원문: 식약처 의약품안전나라
